Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genome Mapping Reveals Drug Resistance Mutation in Peruvian Malaria Parasites

By LabMedica International staff writers
Posted on 22 Sep 2010
Researchers have used advanced genomic techniques to map the genome of the malaria parasite Plasmodium falciparum in a carefully defined geographical area in Peru and found a mutation that causes the parasite to become resistant to the commonly used drug clindamycin.

Investigators at the Scripps Research Institute (La Jolla, CA, USA) and collaborators from other institutions studied 14 P. More...
falciparum patient isolates taken recently from the Iquitos region of the Peruvian Amazon, an area prone to development of drug resistance, as malaria was eliminated there in the 1960s but reemerged in the 1990s. Samples were analyzed using genome scanning, a microarray-based technique that delineates the majority of single-base changes, indels (mutation class that includes both insertions, deletions, and the combination thereof), and copy number variants distinguishing the coding regions of two clones.

Results published in the September 9, 2010, online edition of the journal Genome Research revealed that the parasite population in the Peruvian Amazon bore only a limited number of genotypes with low recombination frequencies. Despite the essentially clonal nature of some isolates, there were high frequencies of mutations in subtelomeric highly variable genes and internal var genes, indicating mutations arising during self-mating or mitotic replication.

Of particular interest was the identification of a mutation in a noncoding RNA gene that conferred resistance to the antibiotic clindamycin, a lincosamide drug commonly administered in combination with quinine to treat pregnant women and infants for malaria in Peru.

"We were surprised to find that the parasite populations in Peru were much more homogeneous than expected,” said senior author Dr. Elizabeth Winzeler, associate professor of cell biology at the Scripps Research Institute. "The data suggested that the malaria parasites from Iquitos patients were closely related, with some patients harboring parasites that were nearly clones of each other.”

"This was the first-ever demonstrated case of clindamycin resistance,” said Dr. Winzeler. "The data also show parasites could be resistant to related compounds, such as mirincamycin, that are under development. Our findings emphasize the importance of placing new antimalarial compounds in the drug development pipeline, especially compounds with novel mechanisms of actions.”

Related Links:
Scripps Research Institute




Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.